Expert Opinion on Investigational Drugs

Article	Citations
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD	110
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL	83
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	82
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	78
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	74
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	72
Theranostic strategies in sarcoma: preliminary clinical evidence	63
Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development	62
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases	58
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men	55
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	51
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	45
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome	44
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies	43
Management of inflammaging in kidney diseases: focusing on the current investigational drugs	38
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	37
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval	31
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies	30
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis	30
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors	29
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials	28
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials	28
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development	28
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?	27
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su	26

Endothelin receptor antagonists for diabetic kidney disease: back to the future?	26
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets	24
Investigational drugs for the treatment of dysmenorrhea	23
Potassium channel modulators and schizophrenia: an overview of investigational drugs	22
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease	20
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia	19
Emerging treatments for chronic urticaria	19
Recent developments in adjunct therapies for type 1 diabetes	18
Current options and investigational drugs for the treatment of eosinophilic esophagitis	18
IgA nephropathy: an overview of drug treatments in clinical trials	18
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer	18
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials	17
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer	17
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development	17
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics	17
Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study	16
Investigational drugs for immune thrombocytopenia	16
Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1	16
Duchenne muscular dystrophy: promising early-stage clinical trials to watch	16
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists	16
Frontotemporal dementia: from genetics to therapeutic approaches	16
Investigational new drugs for the treatment of leishmaniasis	15
What is the progress of experimental drug development for fibromyalgia?	15
Current experimental and early investigational agents for cardiac fibrosis: where are we at?	15
Preclinical therapeutics for sickle cell disease: modern developments and future considerations	15
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration	15
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options	15
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal	15
Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials	15
Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer	15
NF1 alterations in cancers: therapeutic implications in precision medicine	14
Novel systemic treatment approaches for metastatic pancreatic cancer	14
Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021	14
Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents	13
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations	13
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)	13
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease	12
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions	12
Assessing the clinical progress of the bispecific nanobody sonelokimab	12
Progress in the treatment of anal cancer: an overview of the latest investigational drugs	12
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects	12
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)	11
Immunotherapeutic strategies for treating opioid use disorder and overdose	11
JAK inhibitors for rheumatoid arthritis	11
Navafenterol for chronic obstructive pulmonary disease therapy	11
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici	11
Inflammatory myopathies: shedding light on promising agents and combination therapies in clinical trials	11
Investigational thrombolytic drugs for acute ischemic stroke	11
Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials	11
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa	11

Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents	11
Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials	11
Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps	11
Investigational drugs for the treatment of olfactory dysfunction	11
Clinical development of tri-specific antibodies for immune-oncology	10
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study	10
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies	10
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia	10
Investigational new drugs for the treatment of Dravet syndrome: an update	10
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus	10
JAK inhibitors in crohn’s disease: ready to go?	10
Emerging neuroprotective interventions in periventricular leukomalacia - A systematic review of preclinical studies	10
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer	10
Camrelizumab: an investigational agent for hepatocellular carcinoma	9
Pharmacological agents for bone fracture healing: talking points from recent clinical trials	9
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid recep	9
Assessing potential of psilocybin for depressive disorders	9
Prospects of current AXL-targeting therapies in early phase cancer trials	9
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers	9
Inflammation and Huntington’s disease – a neglected therapeutic target?	9
Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections	9
The impact of current investigational drugs for acne on future treatment strategies	9
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension	9
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis	9
Emerging agents for the treatment and prevention of stroke: progress in clinical trials	9
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials	9
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs	9
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma	9
Novel investigational drugs for alopecia areata and future perspectives	8
Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials	8
Mantle cell lymphoma: what clinical progress in the last 5 years?	8
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials	8
Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?	8
Novel agents to treat adrenal insufficiency: findings of preclinical and early clinical trials	8
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-c	8
Investigational anti IL-13 asthma treatments: a 2023 update	8
A VEGF gene therapy approach for the treatment of patients with coronary artery disease and refractory angina: assessment of clinical development	8
Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets	8
Retinal stroke: research models, targets and experimental drugs	8
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress	8
Islatravir: evaluation of clinical development for HIV and HBV	8
Preclinical prospects of investigational agents for hearing loss treatment	8
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH	8
Will new investigational drugs change the way we treat Charcot-Marie-Tooth disease?	7
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents	7
Investigational drugs for the treatment of acromegaly: new agents to transform therapy	7
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects	7
Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease	7
Investigational drugs for ischemic stroke: what’s in the clinical development pipeline for acute phase and prevention?	7
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review	7
Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma	7
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs	7
Insights into the anti-inflammatory and anti-arthritic potential of 3-Acetyl-11-keto-β-Boswellic Acid as a therapeutic approach in Rheumatoid Arthritis	7
Investigational drugs in early phase trials for myelofibrosis	7
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity	7
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape	7
Investigational drugs in early clinical development for portal hypertension	7
Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study	7
Psoriasis: talking points from recent clinical trials	7
What have we learned from past failures of investigational drugs for Alzheimer’s disease?	7
Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody–drug conjugate	7
Fibroblast growth factor therapies in biliary tract cancers: current and future state	7
Experimental drugs for the prevention or treatment of sensorineural hearing loss	7
Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension	6
AXS-05: an investigational treatment for Alzheimer’s disease-associated agitation	6
Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects	6
Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications	6
Retatrutide: a triple incretin receptor agonist for obesity management	6
Experimental drugs for Friedrich’s ataxia: progress and setbacks in clinical trials	6
Investigational new drugs to treat brain metastasis from non-small cell lung cancer	6
Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis	6
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects	6
Bomedemstat as an investigative treatment for myeloproliferative neoplasms	6
Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study	6
Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials	6
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies	6
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects	6
Correction	6
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer	6
Psoriasis: a focus on upcoming oral formulations	6

Developments and challenges for new and emergent preparations for male hypogonadism treatment	6
Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials	5
Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?	5
A comprehensive overview of investigational elastase inhibitors for the treatment of acute respiratory distress syndrome	5
Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development	5
Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon’s ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: res	5
T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development	5
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled do	5
Investigational drugs inhibiting complement for the treatment of geographic atrophy	5
Long COVID [post-acute sequelae of coronavirus disease 2019]: experimental drugs for cardiopulmonary complications	5
First-in-human phase I studies of YJ001 spray applied to local skin in healthy subjects and patients with diabetic neuropathic pain	5
A focused report on IFN-1 targeted therapies for lupus erythematosus	5
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action	5
Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics	5
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study	5
A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion prote	5
Clinical development of BPS804 for osteogenesis imperfecta: from failure to fruition?	5
Zanzalintinib (XL092): a next-generation tyrosine kinase inhibitor—comprehensive review of early safety & efficacy data	5
Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials	5
Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation	5
Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation	4
Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer	4
Emerging therapies for overactive bladder: preclinical, phase I and phase II studies	4
ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease	4
Experimental and new investigational drugs for the treatment of uterine fibroids	4
Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease	4
Early stage clinical trials for the treatment of hemophilia A	4
Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments	4
Sprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis	4
Acetylcholine and muscarinic receptor targeting in bipolar disorder: does xanomeline-trospium chloride and other investigational muscarinic agonists hold promise as mechanistically informed treatments	4
Factor IX stimulants in preclinical and early phase trials for hemophilia B treatment	4
Novel investigational treatments for ventilator-associated pneumonia and critically ill patients in the intensive care unit	4
Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure	4
Avasopasem for the treatment of radiotherapy-induced severe oral mucositis	4
Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis	4
CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation	4
Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline	4
The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke	4
Insulin sensitizers in 2023: lessons learned and new avenues for investigation	4
Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?	4
Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia	3
Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies	3
Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection	3
Pepinemab: a SEMA4D antagonist for treatment of Huntington’s and other neurodegenerative diseases	3
Metabolic dysfunction and insulin sensitizers in acute and chronic disease	3
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, pharmacodynamic, safety, tolerability, and immunogenicity profiles of biosimilar candidat	3
The role of phosphodiesterase 9A inhibitors in heart failure	3
Investigational drugs in clinical trials for macular degeneration	3
Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?	3
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?	3
An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension	3
Investigational follicle-stimulating hormone receptor agonists for male infertility therapy	3
From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?	3
KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases	3
Venetoclax in acute myeloid leukemia	3
Design strategy and research progress of multifunctional nanoparticles in lung cancer therapy	3
Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer	3
Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what’s new?	3
Atezolizumab: an investigational agent for the treatment of biliary tract cancer	3
Evaluation of pharmacokinetic and pharmacodynamic similarity of an IDegAsp biosimilar versus the originator in healthy Chinese volunteers	3
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential	3
A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects	3
Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers	3
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond	3
Prospects for multi-focal motor neuropathy treatment by complement inhibition	3
New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature	3
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer	3
Polyvalent immunoglobulin therapy: preclinical evidence and potential for treating chemotherapy-induced peripheral neuropathy	3
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions	3
Prospect of CAR T-cell therapy in acute myeloid leukemia	3
Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjects	3
Experimental drugs in randomized controlled trials for long-COVID: what’s in the pipeline? A systematic and critical review	3
Investigational treatment strategies in glioblastoma: progress made and barriers to success	3
Tolerability, safety, and pharmacokinetics of GR1603 injection in healthy subjects: a randomized, double-blind, placebo-controlled single-dose escalation clinical trial	3
Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development	3
Investigational drugs for HIV: trends, opportunities and key players	3